Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • NCD 2025
NET Nurse
Donate

Home » Advocacy » Unicorn Foundation Speaks at Senate Inquiry

Unicorn Foundation Speaks at Senate Inquiry

  • October 11, 2015

On September 17 the Senate released their report from the inquiry with key recommendations that we hope are implemented.

Below is some of the key recommendations from the report released on 17 September, that the Unicorn Foundation endorses as a result of the Senate Inquiry. 

Key Recommendations

Recommendation 1 included:

  • that the Australian Government initiate a comprehensive review of the system for the registration and subsidisation of medicines. The review should examine:
  • all available pathways for registration and listing of new medicines including making provision for utilisations of assessments conducted by comparable overseas regulators; provision for clinicians and/or patient groups to apply for extension of existing registrations to additional indications, managed access programs and risk-sharing, and the adoption of more flexible evidential requirements
  • ensuring greater transparency throughout the assessment process
  • options for expanding post-market review of medicines
  • enhancing and formalising mechanisms for consumers and clinicians to play a more central and substantial role in the evaluation of new medicines and indications, including;      
  • consideration of options for expanding consumer and clinician representation on the PBAC;
  • enhancing existing avenues for stakeholder input, including the use of consumer and patient hearings

Recommendation 2 included:

  • the committee recommends that the Australian Government commission a review of current data collection mechanisms for cancer medicines, including identification of:
  • obstacles to the integration of exisiting databases and potential avenues for addressing these;
  • opportunities to incorporate data from post-market evaluations; and
  • avenues for capturing data relating to the off-label use of cancer medicines

Recommendation 3 included:

  • the committee recommends that the Australian Government establish a Steering Committee to examine the feasibility of establishing a national register of cancer medicines

We implore our patients and supporters to get behind these recommendations that urgent in the care of cancers and in particular rare cancers. 

Please write to your local member and ask them to endorse the recommendations that have come out of this historical inquiry click here for a list of all representatives.

For the Senate Inquiry report and recommendations download here

To view the day's proceedings click here or review the Unicorn Foundation submission on PDF format click here.

Share this post

Recent posts

Rare Cancers Roundtable

September 26, 2025

Shining a Light for World Neuroendocrine Cancer Day – Help Us Light Up Australia

September 26, 2025

Celebrating Shane Kent’s Arch2Arc Journey and Fundraising

September 20, 2025

Will Norman Nurse Webinar on Neuroendocrine Cancer

September 19, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPrevious2015 INCA Patient Summit
NextFederal Health Department GrantNext

Related Posts

PCPA Cancer Summit

  The Private Cancer Physicians of Australia (PCPA) hosted its Annual Meeting: Cancer Summit 2025 in Sydney on 13 September, bringing together clinicians, researchers, and

SCAN 2025 is now open – we need your voice

SCAN 2025 is now open – we need your voice.  As a proud member of the International Neuroendocrine Cancer Alliance (INCA), NeuroEndocrine Cancer Australia is excited

Medicines Australia Horizon Scanning – Advancing Patient Access and Genomics

NeuroEndocrine Cancer Australia CEO Meredith Cummins joined a panel discussion at the Medicines Australia Horizon Scanning event, accompanied by Media and External Relations Manager Ciara

CanForum 2025: Now it’s personal: Access and equity for all

On 2nd September 2025, NeuroEndocrine Cancer Australia CEO Meredith Cummins and Media and External Relations Manager Ciara Connolly attended CanForum 2025, a leading national conference

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin